OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more

OncoAlert Colloquium Day 4: GI oncology and EONS

OncoAlert Colloquium Day 3: Breast cancer

OncoAlert Colloquium Day 2: Lung cancer and MASCC

OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology

The RxPONDER trial and its impact on best clinical practice

OncoAlert and ecancer weekly round up for October 11th - October 16, 2021

Enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-sensitive prostate cancer

Adding abiraterone acetate plus prednisolone to standard therapy lengthens survival in non-metastatic high-risk prostate cancer

OncoAlert and ecancer - ESMO 2021 Day 5

OncoAlert and ecancer - ESMO 2021 Day 3

First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer